Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation

Rollier, Christine S.; Dold, Christina; Blackwell, Luke; Linder, Aline; Silva-Reyes, Laura; Clutterbuck, Elizabeth A.; Davis, Kimberly; Ford, Karen; Liu, Xinxue; Holland, Ann; Chan, Hannah; Harbinson, Holly; O’Connor, Daniel; Borrow, Ray; Snape, Matthew D; Pollard, Andrew J.

doi:10.1016/j.vaccine.2022.04.085

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These factors negatively affect the cost effectiveness of an adolescent program for MenB vaccines ( 9 ). A low-cost, single-dose MenB vaccine capable of inducing sustained protective immune responses would be well positioned ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen’s localization and conformation or lead to unwanted glycosylation. Here, we investigated the potential use of an adenoviral-vectored vaccine platform for capsular group B meningococcus (MenB). Vector-based candidate vaccines expressing MenB antigen factor H binding protein (fHbp) were generated, and immunogenicity was assessed in mouse models, including the functional antibody response by serum bactericidal assay (SBA) using human complement. All adenovirus-based vaccine candidates induced high antigen-specific antibody and T cell responses. A single dose induced functional serum bactericidal responses with titers superior or equal to those induced by two doses of protein-based comparators, as well as longer persistence and a similar breadth. The fHbp transgene was further optimized for human use by incorporating a mutation abrogating binding to the human complement inhibitor factor H. The resulting vaccine candidate induced high and persistent SBA responses in transgenic mice expressing human factor H. The optimized transgene was inserted into the clinically relevant ChAdOx1 backbone, and this vaccine has now progressed to clinical development. The results of this preclinical vaccine development study underline the potential of vaccines based on genetic material to induce functional antibody responses against bacterial outer membrane proteins.

show abstract

Section: Introductionmentioning

confidence: 99%

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review

Palmieri,

Moscara,

Tafuri

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Two vaccines are available to prevent serogroup B meningococcal disease, i.e. the four-component meningococcal serogroup B vaccine (4CMenB) and the bivalent-factor-H-binding-protein meningococcal serogroup B vaccine (MenB-fHbp). Currently, 4CMenB is offered as part of routine infant immunization schedules. Available immunogenicity data showed a progressive decline in protective serum bactericidal antibodies (SBA) titers, with a re-enhancement following a booster dose during infancy. Responses did not seem to be long-lasting and vaccinated individuals might be at risk of meningococcal diseases duriṇg adolescence. Only one study evaluated the possibility to administer a single booster dose to immunocompetent adolescents who received a primary series during infancy. Despite a high proportion of enrollees achieving protective SBA levels 28 days post-booster, titers tended to decrease 1 year after. Immunocompetent adolescents who received a primary series and a booster during the first two years of life might rather benefit from re-vaccination against MenB; current evidence does not support the possibility of a booster.

show abstract

Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation

Cited by 2 publications

References 32 publications

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review

Contact Info

Product

Resources

About